Browsed by
Tag: Alzheimer Society Research Program

Research Video Series: Introducing Danielle Alcock

Research Video Series: Introducing Danielle Alcock


Danielle’s personal experience inspired her to pursue research in the field of continuity of care. She will assess existing services through the use of oral narratives by female, Indigenous caregivers for a loved one diagnosed with alcohol-related dementia and will make recommendations based on their experience.

Coming from a First Nations family, it was difficult to navigate the healthcare system dealing with jurisdictional barriers, stigma and a lack of resources. As a caregiver, there are no existing supports for alcohol-related dementia that are culturally safe.
-Danielle Alcock

Danielle Alcock

Alzheimer Society Research Program Quality of Life Grant Recipient in Alzheimer’s disease and dementia – $66,000
Project: Oral narratives of female Indigenous caregivers for loved ones diagnosed with alcohol-related dementia.

Read about more of our grant and award recipients here.

Announcing the top 10 Canadian dementia research priorities

Announcing the top 10 Canadian dementia research priorities

[Le texte en français suit l’anglais ci-bas.]

By Drs. Katherine McGilton and Jennifer Bethell

Over the course of the past year, we asked Canadians affected by dementia—either personally or through their work—for their unanswered questions about living with dementia, dementia prevention, treatment and diagnosis. This study, also known as the Canadian Dementia Priority Setting Partnership, set out to identify the top 10 dementia research priorities, and to share them with Canadian researchers and research funding organizations.

We thank the over 1200 participants who shared their insights. Thousands of questions were submitted and the shortlist was debated at an in-person workshop, held in Toronto on June 8-9, 2017.

Canadian Dementia Priority Setting Partnership workshop,
June 8-9, 2017, in Toronto

The workshop brought together 28 participants from across Canada—persons with dementia, family members, health and social care providers and members of organizations that represent persons with dementia. Participants worked in small teams and as a group to discuss each question and decide what matters most to them.

Here are the top 10 dementia research priorities, according to Canadians affected by dementia:

  1. What is the impact of stigmas associated with dementia and mental health issues on persons with dementia and their families? What are effective ways of reducing the stigma experienced by persons with dementia and their friends, family and caregivers/care partners?
  2. What can be done to support emotional wellbeing, including maintaining a sense of dignity, for persons with dementia?
  3. Among persons with dementia, what is the impact of early treatment on quality of life, disease progression and cognitive symptoms?
  4. How can the health system build and sustain the capacity to meet the health and social care needs of persons with dementia and their friend or family caregivers/care partners?
  5. What services, supports and therapies for friend or family caregivers/care partners of persons with dementia would improve or maintain health, wellbeing and quality of life for persons with dementia and their friends or family caregivers/care partners?
  6. After dementia is diagnosed, what would help persons with dementia and their friends, family and caregivers/care partners get the information, treatment, care and services they may need?
  7. What dementia-related skills and knowledge should health and social care providers have? What are effective ways of providing them with these skills and this knowledge? How can the number of health and social care providers who have these skills and this knowledge be increased?
  8. What enables the creation of dementia-friendly communities? What impact do dementia-friendly initiatives have on persons with dementia and their friends, families and caregivers/care partners?
  9. What would ensure implementation and sustainability of best practices for dementia care within and across health care settings, including effective approaches to providing person-centred care?
  10. Among persons with dementia, what are the effects of non-pharmacological treatments compared to pharmacological treatments on behavioural and psychological symptoms of dementia? Can non-pharmacological treatments replace, reduce or be used in conjunction with pharmacological treatments for managing behavioural and psychological symptoms of dementia?

The Alzheimer Society Research Program will use these results to help bring the voices of Canadians affected by dementia into the research agenda. These priorities will also be shared with researchers and other research-funding organizations in hopes of stimulating more research in these areas.

The Canadian Dementia Priority Setting Partnership was funded by the Alzheimer Society Research Program as part of the Alzheimer Society’s commitment to the Canadian Consortium on Neurodegeneration in Aging (CCNA). Special thanks to our Steering Group and partner organizations for their involvement and assistance in the study.


ANNONCE DES DIX PRIORITÉS DE RECHERCHE SUR LES MALADIES COGNITIVES AU CANADA

researcher
Par les Dres Katherine McGilton et Jennifer Bethell

Au cours de la dernière année, nous avons demandé aux Canadiens touchés par une maladie cognitive, soit personnellement ou dans le cadre de leur travail, de faire part de leurs questions sans réponses sur la vie avec une maladie cognitive, la prévention, le traitement et le diagnostic. Cette étude, aussi connu sous le nom du Partenariat canadien pour l’établissement des priorités sur les maladies cognitives, visait à identifier les priorités de recherche à l’intention des chercheurs et des organismes de financement.

Nous remercions les plus de 1 200 participants qui ont partagé leurs points de vue. Des milliers de questions ont été soumises et la liste présélectionnée a été débattu lors d’un atelier en personne qui a eu lieu à Toronto les 8 et 9 juin 2017.

Atelier du Partenariat canadien pour l’établissement des priorités sur les maladies cognitives, le 8 et 9 jun 2017 à Toronto

L’atelier a mis à contribution 28 participants de tout le Canada, dont des personnes atteintes d’une maladie cognitive, des aidants familiaux, des fournisseurs de soins de santé et de services sociaux, et des membres d’organisations qui représentent des personnes atteintes d’une maladie cognitive. Les participants ont discuté au sein de petites équipes et en commun de chacune des questions afin de décider ce qui est important pour eux.

Voici les 10 priorités de recherche les plus importantes selon les Canadiens touchés par une maladie cognitive :

  1. Quelles sont les répercussions de la stigmatisation entourant les maladies cognitives et la santé mentale sur les personnes atteintes d’une maladie cognitive et leur famille? Quels sont les moyens efficaces de réduire la stigmatisation vécue par les personnes atteintes d’une maladie cognitive, leurs amis, famille et aidants/partenaires des soins?
  2. Que peut-on faire pour soutenir le bien-être émotionnel, notamment le sentiment de dignité, des personnes atteintes d’une maladie cognitive?
  3. Quelles sont les conséquences du traitement précoce sur la qualité de vie, la progression de la maladie et les symptômes des personnes atteintes d’une maladie cognitive?
  4. Comment le système de santé peut-il développer et maintenir ses capacités de manière à répondre aux besoins des personnes atteintes d’une maladie cognitive et de leurs amis ou aidants familiaux/partenaires de soins en matière de soins de santé et de services sociaux?
  5. Quels services, appuis et thérapies à l’intention des amis et aidants familiaux/partenaires de soins des personnes atteintes d’une maladie cognitive permettent d’améliorer ou de maintenir la santé, le bien-être et la qualité de vie des personnes atteintes d’une maladie cognitive et de leurs amis, ou famille et aidants naturels/partenaires de soins?
  6. Une fois la maladie cognitive diagnostiquée, qu’est-ce qui aiderait les personnes atteintes et leurs amis, famille et aidants/partenaires de soins à obtenir l’information, les traitements, les soins et les services dont ils pourraient avoir besoin?
  7. Quelles compétences et connaissances devraient posséder les fournisseurs de soins de santé et de services sociaux dans le domaine des maladies cognitives? Quels moyens efficaces pourrait-on utiliser pour leur transmettre ces compétences et connaissances? Comment augmenter le nombre de fournisseurs de soins de santé et de services sociaux qui possèdent ces compétences et connaissances?
  8. Qu’est-ce qui facilite la création de collectivités amies des personnes atteintes d’une maladie cognitive? Quelles sont les conséquences de ces collectivités sur les personnes atteintes d’une maladie cognitive et leurs amis, famille et aidants/partenaires de soins?
  9. Qu’est-ce qui assurerait la mise en application et la viabilité des meilleures pratiques en matière de soins dans les établissements qui accueillent des personnes atteintes d’une maladie cognitive, y compris en ce qui a trait aux soins centrés sur la personne?
  10. Quels sont les effets des traitements non pharmacologiques à comparer aux traitements pharmacologiques sur les symptômes comportementaux et psychologiques des personnes atteintes d’une maladie cognitive? Les traitements non pharmacologiques peuvent-ils remplacer, réduire ou être utilisés en association avec les traitements pharmacologiques pour la gestion des symptômes comportementaux et psychologiques des maladies cognitives?

Le Programme de recherche de la Société Alzheimer utilisera ces résultats pour faire entendre la voix des Canadiens touchés par les maladies cognitives dans les futures décisions en ce qui a trait à la recherche. Ces priorités seront également transmises aux chercheurs et aux autres organismes de financement dans l’espoir de stimuler la recherche dans ces domaines de prédilection.

Le Partenariat canadien pour l’établissement des priorités sur les maladies cognitives a été financé par le Programme de recherche de la Société Alzheimer dans le cadre de son engagement envers le Consortium canadien en neurodégénérescence associée au vieillissement (CCNV). Nous remercions tout particulièrement notre groupe d’orientation et les organisations partenaires pour leur participation et contribution à cette etude.

Research Video Series: Introducing Sharon Koehn

Research Video Series: Introducing Sharon Koehn

Too often, immigrants in Canada don’t receive the help and support they need because of barriers like language and culture.

That’s why Dr. Sharon Koehn from Simon Fraser University, British Columbia, is on a mission to identify ways to foster relationships of trust among immigrants affected by dementia and encourage them to reach out to multicultural agencies.

Living with Alzheimer’s disease and other dementias is hard enough; it’s essential that we ensure that we don’t make it even harder by not paying attention to how and if people access appropriate information and care.
-Dr. Sharon Koehn

Dr. Sharon Koehn

Quality of Life Grant Recipient in Alzheimer’s disease and dementia – $119,623
Project: Building trust to facilitate access to dementia care for immigrant older adults: the role of the multicultural services sector.

Read about more of our grant and award recipients here.

Research Video Series: Introducing Dr. Edith Hamel

Research Video Series: Introducing Dr. Edith Hamel


Dr. Edith Hamel’s research focuses on the supply of blood to the brain, which is so important as the brain doesn’t have a reserve of oxygen and glucose – the main fuel for neurons. This project could uncover ways to slow down the progression of vascular dementia, possibly through the use of therapies already available for the treatment of diabetes and hypercholesterolemia. Dr. Hamel is a professor at McGill University in Montreal.

I strongly believe that real possibilities exist to prevent or delay the appearance of Alzheimer’s disease or vascular dementia.
-Dr. Edith Hamel

Dr. Edith Hamel

Biomedical Grant Recipient in Alzheimer’s disease and dementia – $150,000
Project: Role of compromised cerebral circulation in susceptibility to cognitive failure.

Read about more of our grant and award recipients here.

Research Video Series: Introducing Iva Brunec

Research Video Series: Introducing Iva Brunec


Iva Brunec is investigating how memories about the duration and order of events are created in healthy brains, and how this ability changes in those at risk for dementia. Is the ability to encode and recall information about time one of the first functions to break down with Alzheimer’s disease? Does it affect other aspects of memory as a result? This research aims to provide evidence of a sensitive indicator before a diagnosis of dementia even occurs.

Investigating these disorders and aiming to understand what causes them, how they progress, and how they may be alleviated or prevented could enrich the lives of not only those living with dementia but also the networks of their families and caregivers.
-Iva Brunec

Iva Brunec

Biomedical Doctoral Award Recipient in Alzheimer’s Disease and Dementia – $66,000
Project: Investigating the hippocampal role in encoding temporal information as a possible

Read about more of our grant and award recipients here.

Research Video Series: Introducing Hadir AlQot

Research Video Series: Introducing Hadir AlQot


Hadir AlQot aims to further our knowledge and understanding of the complex mechanisms underlying Alzheimer’s disease. Specifically, she aims to investigate a novel aspect of the cholinergic system and its vulnerability in Alzheimer’s disease in relation to key pathological features and cognitive decline. Hadir AlQot is doctoral student at the University of Western Ontario.

It is my hope that this research will help unravel potential novel therapeutic targets for Alzheimer’s disease and other dementias.
-Hadir AlQot

Hadir AlQot

Biomedical Doctoral Award Recipient in Alzheimer’s disease and dementia – $66,000
Project: The functional role of nuclear 82-kDa ChAT in APP metabolism and its potential neuroprotective significance

Read about more of our grant and award recipients here.

Research Video Series: Introducing Dr. Lisa M. Munter

Research Video Series: Introducing Dr. Lisa M. Munter


Dr. Lisa M. Munter will be investigating a novel aspect of the cholesterol metabolism with respect to Alzheimer’s disease. Her goal is to understand how dietary cholesterol affects generation of harmful amyloid peptides. She hopes to reveal whether certain lipoprotein particles of the blood may trigger amyloid generation in the brain. Dr. Munter is a researcher and professor at McGill University and the recipient of an ASRP biomedical grant.

A long and prosperous life should end with human dignity.
-Dr. Lisa M. Munter

Dr. Lisa M. Munter

Biomedical Grant Recipient in Alzheimer’s disease and dementia – $150, 000
Project: Peripheral and central pathways of cholesterol-induced Alzheimer’s disease pathology

Read about more of our grant and award recipients here.

Research Video Series: Introducing Marco Prado

Research Video Series: Introducing Marco Prado


Dr. Marco Prado’s research aims to address the mechanisms by which deficient cholinergic circuits contribute to dementia. He is an Alzheimer Society Research Program Biomedical Research Grant recipient and a professor at the University of Western Ontario.

Let’s make sure that aging does not mean losing one’s identity.
-Dr. Marco Prado

Dr. Marco Prado

Biomedical Grant Recipient in Alzheimer’s disease and dementia – $149,128
Project: Mechanisms of anti-cholinergic activity mediated dementia and Alzheimer’s pathology

Read about more of our grants and awards recipients here.

Research Video Series: Introducing Laura Hamilton

Research Video Series: Introducing Laura Hamilton


Dr. Laura Hamilton is testing the efficacy of a new therapeutic target (stearoyl CoA desaturase (SCD)-1) to improve learning and memory deficits in Alzheimer’s disease using a mouse model. Laura is a postdoctoral fellow at the University of Montréal and is this year’s Alzheimer Society Research Program Spark Award Recipient.

The potential to contribute to a better quality of life for millions of people motivates me every day.
-Dr. Laura Hamilton

Dr. Laura Hamilton

Spark Postdoctoral Fellowship in Alzheimer’s Disease (Biomedical) – $100,000
Project: Triggers and behavioural consequences of elevated oleic acid in the Alzheimer’s disease brain

Read about more of our grants and awards recipients here.

Research Video Series: Introducing Stephanie Chamberlain

Research Video Series: Introducing Stephanie Chamberlain


Trained as a personal support worker in long-term care, Stephanie Chamberlain is currently pursuing her PhD at the University of Alberta. There, she is assessing the impact of court-appointed public guardianship on the health and care needs of long-term care residents. Stephanie is the Alzheimer Society Research Program’s first Revera Scholar.

It is essential that we improve quality of life and quality of care to those with Alzheimer’s disease and dementia because how we treat a life that has been lived is reflective of our essential humanity.
-Stephanie Chamberlain

Stephanie Chamberlain

Revera Scholar Doctoral Award in Alzheimer’s disease (Quality of Life) – $66,000
Project: Unrepresented older adults: The impact of public guardianship on resident health and care needs in long-term care

Read about more of our grants and awards recipients here.